More details on the breakthrough technology of Israel’s Nectin (see here previously). Monoclonal antibodies, with toxins attached, are sent directly to the cancer cell to break its ability to immobilize the body’s immune system. Clinical trials are expected to start in early 2022.

https://www.israel21c.org/new-drug-candidate-could-boost-potential-of-immunotherapy/